Amplia Therapeutics Limited
INNMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $3,784 | $4,453 | $1,189 | $1,983 |
| % Growth | -15% | 274.3% | -40% | – |
| Cost of Goods Sold | $211 | $442 | $73 | $3 |
| Gross Profit | $3,573 | $4,011 | $1,116 | $1,980 |
| % Margin | 94.4% | 90.1% | 93.8% | 99.8% |
| R&D Expenses | $7,529 | $5,805 | $4,687 | $3,772 |
| G&A Expenses | $2,672 | $2,604 | $2,198 | $1,636 |
| SG&A Expenses | $2,751 | $2,690 | $2,715 | $1,852 |
| Sales & Mktg Exp. | $79 | $86 | $517 | $216 |
| Other Operating Expenses | -$190 | -$59 | $0 | $0 |
| Operating Expenses | $10,089 | $8,436 | $7,402 | $5,624 |
| Operating Income | -$6,516 | -$4,425 | -$6,189 | -$3,643 |
| % Margin | -172.2% | -99.4% | -520.3% | -183.7% |
| Other Income/Exp. Net | -$56 | -$4,516 | -$54 | -$1 |
| Pre-Tax Income | -$6,572 | -$8,941 | -$6,242 | -$3,644 |
| Tax Expense | $0 | -$4,438 | $0 | $0 |
| Net Income | -$6,572 | -$4,503 | -$6,242 | -$3,644 |
| % Margin | -173.7% | -101.1% | -524.8% | -183.7% |
| EPS | -0.021 | -0.023 | -0.032 | -0.025 |
| % Growth | 7.8% | 28% | -28.8% | – |
| EPS Diluted | -0.021 | -0.023 | -0.032 | -0.025 |
| Weighted Avg Shares Out | 307,104 | 194,014 | 193,975 | 145,549 |
| Weighted Avg Shares Out Dil | 307,209 | 194,006 | 193,975 | 145,549 |
| Supplemental Information | – | – | – | – |
| Interest Income | $220 | $145 | $97 | $1 |
| Interest Expense | $0 | $78 | $54 | $1 |
| Depreciation & Amortization | $10 | $10 | $73 | $3 |
| EBITDA | -$6,782 | -$4,560 | -$7,264 | -$3,640 |
| % Margin | -179.2% | -102.4% | -610.7% | -183.6% |